Integrate | $17,000,000 | (Feb 13, 2026)
daypass.com | $2,000,000 | (Feb 13, 2026)
CYDELPHI | $3,000,000 | (Feb 13, 2026)
Certified by Founder
Lodge
ImmunoScape
start up
Singapore
- Singapore
- 26/09/2022
- Unknown
- $14,000,000
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.
To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
- Industry Biotechnology Research
- Website https://immunoscape.com/
- LinkedIn https://www.linkedin.com/company/immunoscape/
Related People
Choon-Peng (Choon) NgFounder
Singapore -
Singapore
General Management. Cross functional and cross geography experience.
Maestro Tech, Inc. | $1,200,000 | (Feb 13, 2026)
Ever | $31,000,000 | (Feb 13, 2026)
Manufact (formerly mcp-use) | $6,300,000 | (Feb 13, 2026)
Reflow | $15,000,000 | (Feb 13, 2026)
Santé(US) | $7,600,000 | (Feb 13, 2026)
Alva Energy | $33,000,000 | (Feb 13, 2026)
Project Omega | $12,000,000 | (Feb 13, 2026)
Brandlight | $30,000,000 | (Feb 12, 2026)
Inertia | $450,000,000 | (Feb 12, 2026)